Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected

Metagenomi Inc (NASDAQ:MGX) Reports Q2 2025 Earnings: Revenue Beats Estimates, Loss Narrows

Metagenomi Inc, a precision genetic medicines company, reported its second-quarter 2025 financial results, delivering a mixed performance relative to analyst expectations. The company posted revenue of $8.51 million, surpassing the consensus estimate of $7.80 million. Meanwhile, its net loss per share came in at -$0.54, an improvement over the anticipated -$0.63. Despite the earnings beat, shares dipped slightly in after-hours trading, reflecting cautious investor sentiment amid broader market conditions.

Key Financial Highlights

• Revenue: $8.51M (vs. $7.80M estimate) – 9.1% beat
• EPS: -$0.54 (vs. -$0.63 estimate) – 14.6% narrower loss than expected
• Cash Position: $205.0M, providing runway into 2027
• R&D Expenses: $22.5M (down from $28.3M YoY)
• G&A Expenses: $7.0M (down from $8.6M YoY)

The revenue beat was driven by collaboration income, while cost reductions contributed to a smaller-than-expected loss. However, the company remains in a pre-revenue stage for its core therapeutic programs, with most income stemming from partnerships.

Market Reaction

Following the earnings release, Metagenomi’s stock declined approximately 2.2% in after-hours trading. This reaction suggests that while the financials were better than expected, investors may be weighing the following factors:

• Cash Burn & Long-Term Viability: Despite a strong cash position, the company continues to operate at a loss, with net losses widening sequentially.
• Pipeline Progress: While preclinical data for its hemophilia A program (MGX-001) showed promise, regulatory filings (IND/CTA) are not expected until 2026, delaying potential commercialization.
• Macro Sentiment: Biotech stocks, particularly those in gene editing, remain volatile as investors assess clinical timelines and funding needs.

Business & Pipeline Updates

The earnings release highlighted several key developments:

• MGX-001 (Hemophilia A): Long-term non-human primate data showed durable Factor VIII activity, though the company is exploring alternative constructs for optimization.
• Platform Advancements: Presented early proof-of-concept data at ASGCT, including compact nucleases for extrahepatic editing and CRISPR-associated transposases (CAST) for large gene integration.
• Corporate Moves: Appointed Dr. Laurence Reid to the Board of Directors and established an R&D committee to guide scientific strategy.

Outlook & Analyst Estimates

Metagenomi did not provide formal forward guidance, but analysts project:

• Q3 2025 Revenue Estimate: $8.00M
• Q3 2025 EPS Estimate: -$0.66
• Full-Year 2025 Revenue Estimate: $34.81M
• Full-Year 2025 EPS Estimate: -$2.48

Given the lack of explicit company forecasts, investor focus remains on pipeline execution and partnership developments.

Conclusion

Metagenomi’s Q2 results reflect progress in both financial discipline and preclinical research, though the market’s muted reaction suggests lingering concerns over cash burn and timelines. The company’s gene-editing platform continues to show promise, but clinical validation remains a key hurdle.

For detailed earnings estimates and historical performance, view the full data here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making any financial decisions.